Connect with us

Media & Technology

SureSource Fuel Cell Power; the Story of FuelCell Energy Inc (NASDAQ: FCEL)

Published

on

FuelCell Energy Inc (NASDAQ: FCEL) is making a powerful move up the charts in recent weeks skyrocketing of its $2 base and emerging as a volume leader in small cap thanks to growing interest in the burgeoning hydrogen economy. There is a lot to get excited about on FuelCell  as the Company recently secured $8 million from the US Department of Energy to be used for the solid oxide electrolyss technology. Recently Paul Coster an analyst at JP Morgan Chase upgraded his opinion of the stock giving it a major buy rating due to near term catalysts including “major products with Toyota and Exon.” JP Morgan also predicts FuelCell is profitable by 2022 by turning its projected $1.3 million in project backlogs into revenues.

Fuel Cell is a fast growing sector as hydrogen demand increases at a rapid rate with the current global fuel cell market estimated to be worth $170 billion. Large oil Companies such as BP are also ramping up their hydrogen investments. Currently hydrogen supplies less than 5% of the World’s energy but some estimates suggest if may represent up to 25% of the Worlds energy by 2050 representing a $2.5 trillion market opportunity.

FuelCell Energy Inc (NASDAQ: FCEL) based in Connecticut began selling stationary fuel cell power plants commercially in 2003. The Company is now a global leader in sustainable clean energy technologies that address some of the world’s most critical challenges around energy, safety and global urbanization. As a leading global manufacturer of proprietary fuel cell technology platforms, FuelCell Energy is uniquely positioned to serve customers worldwide with sustainable products and solutions for businesses, utilities, governments and municipalities. The Company’s solutions are designed to enable a world empowered by clean energy, enhancing the quality of life for people around the globe. FuelCell targets large-scale power users with our megawatt-class installations globally, and currently offer sub-megawatt solutions for smaller power consumers in Europe. FuelCell customer base includes utility companies, municipalities, universities, hospitals, government entities/military bases and a variety of industrial and commercial enterprises. The Company’s leading geographic markets are currently the United States and South Korea, and it is pursuing opportunities in other countries around the world. SureSource, SureSource 1500, SureSource 3000, SureSource 4000, SureSource Recovery, SureSource Capture, SureSource Hydrogen, SureSource Storage, SureSource Service, SureSource Capital, FuelCell Energy, and FuelCell Energy logo are all trademarks of FuelCell Energy, Inc.

With more than 9.5 million megawatt hours of clean electricity produced, FuelCell Energy is now a global leader in delivering environmentally-responsible distributed baseload power solutions through its proprietary, molten-carbonate fuel cell technology. FuelCell core fuel cell products offer clean, highly efficient and affordable power generation for customers, including the sub-megawatt SureSource 250 TM and SureSource 400 TM in Europe, and the 1.4 MW SureSource 1500TM, the 2.8 MW SureSource 3000TM, and the 3.7 MW SureSource 4000TM globally.  The plants are scalable for multi-megawatt utility applications, microgrid applications, distributed hydrogen, or on-site CHP generation for a broad range of applications.  FuelCell’s proprietary carbonate fuel cell technology generates electricity directly from a fuel, such as natural gas or Renewable Biogas, by reforming the fuel inside the fuel cell to produce hydrogen. This internal, proprietary “one-step” reforming process results in a simpler, more efficient, and cost-effective energy conversion system compared with external reforming fuel cells.

To Find Out the Inside Scoop on FCEL Subscribe to Microcapdaily.com immediately by entering your email below

FCEL

The Company’s fuel cell solution is a clean, efficient alternative to traditional combustion-based power generation and is complementary to an energy mix consisting of intermittent sources of energy, such as solar and wind turbines. FuelCell systems answer the needs of diverse customers across several markets, including utility companies, municipalities, universities, hospitals, government entities and a variety of industrial and commercial enterprises.  The Company provides solutions for various applications, including utility-scale distributed generation, on-site power generation and combined heat and power, with the differentiating ability to do so utilizing multiple sources of fuel including natural gas, Renewable Biogas (i.e., landfill gas, anaerobic digester gas), propane and various blends of such fuels. Our multi-fuel source capability is significantly enhanced by our proprietary gas-clean-up skid.

Fiscal year 2019 was one of transformation for FuelCell Energy. The Company restructured its management team and its operations in ways that are intended to support its growth and achieve profitability and sustainability goals. Recently the Company closed on a new $200 million credit facility with Orion Energy Partners, executed a new Joint Development Agreement with ExxonMobil Research and Engineering Company (“EMRE”), with anticipated revenues of up to $60 million and restructed its business to realize annualized operating savings of approximately $15 million.

On December 4 FuelCell announced completion of the previously announced underwritten public offering of 39,696,320 shares of its common stock, including the underwriters’ exercise, in full, of their option to purchase an additional 5,177,781 shares of common stock from the Company. The offering consists of 25,000,000 shares sold by the Company and 14,696,320 shares sold by certain selling stockholders, resulting in aggregate gross proceeds of $162.5 million to the Company and $95.5 million to the selling stockholders, before deducting the underwriters’ discounts and offering expenses. J.P. Morgan Securities LLC is acting as sole book-running manager. Barclays Capital Inc., Canaccord Genuity LLC, Cowen and Company LLC, Loop Capital Markets LLC, Oppenheimer & Co. Inc., Craig-Hallum Capital Group LLC, and Tuohy Brothers Investment Research, Inc. acted as co-managers for the offering.

For More on FCEL Subscribe Right Now!

Currently making a powerful move up the charts FCEL is an exciting story developing in small caps; FuelCell is a global leader in delivering environmentally-responsible distributed baseload power solutions through its proprietary, molten-carbonate fuel cell technology. FuelCell core fuel cell products offer clean, highly efficient and affordable power generation for customers, including the sub-megawatt SureSource 250 TM and SureSource 400 TM in Europe, and the 1.4 MW SureSource 1500TM, the 2.8 MW SureSource 3000TM, and the 3.7 MW SureSource 4000TM globally.  The Company recently secured $8 million from the US Department of Energy to be used for the solid oxide electrolyss technology. Recently Paul Coster an analyst at JP Morgqn Chase upgraded his opinion of the stock giving it a major buy rating due to near term catalysts including “major products with Toyota and exon. JP Morgan also predicts FuelCell is profitable by 2022 by turning its projected $1.3 million in project backlogs into revenues. Fuel Cell is a fast growing sector as hydrogen demand increases at a rapid rate with the current global fuel cell market estimated to be worth $170 billion. Large oil Companies such as Dutch Shell and BP are also ramping up their hydrogen investments.  Currently hydrogen supplies less than 5% of the Worlds energy but some estimates suggest if may represent up to 25% of the Worlds energy by 2050 representing a $2.5 trillion market opportunity. We will be updating on FCEL when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with FCEL.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in FCEL either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Media & Technology

Global Tech Industries Group Inc (GTII) rally could be just getting started

Published

on

Small-cap stocks have seen a significant increase in the first weeks of January, a trend that is often seen at the start of a new year. This presents an opportunity for investors to capitalize on the surge before it dissipates. The Russell 2000 index, which follows small-cap stocks, has shown a 7.4% increase as of Monday’s close, outperforming the large-cap Russell 1000, which has risen by 5%, and the S&P 500, which has increased by 4.5%.

The “January Effect” rally, where small caps surpass large caps, is a common phenomenon. One such stock that may be benefitting from this January effect is GTII. Global Tech Industries Group Inc (GTII) last traded at $1.86 and closed with double-digit gains of 11.08%.  GTII has a 52-week range of $0.4302 – $8.9700, suggesting a tremendous upside potential from the current levels.

To Find out the inside Scoop on GTII, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What caused the surge in GTII share prices?

For the uninitiated,  Global Tech Industries Group, Inc. (OTCQB: GTII) is a Nevada-based public company focused on acquiring cutting-edge technologies. Last week, GTII announced Board appointed Donald Gilbert to lead a newly created task force that will investigate illegal trading in GTII’s shares. The task force will be responsible for examining and assessing the possibility of illegal and deceptive trading practices by various market players, including market makers, brokers, and hedge funds. In addition, the task force will also advise the Board on potential legal actions against market participants suspected of engaging in unlawful trading activity concerning GTII’s shares. Based on its initial assessment, the task force will also advise the Board on presenting evidence of potential illegal trading activity concerning GTII’s shares to relevant government and regulatory agencies. In essence, Mr. Gilbert will lead the efforts necessary for safeguarding the interests of GTII’s shareholders.

For more on GTII, Subscribe Right Now!

Creatd, Inc.(OTCQB: CRTD) announced today that it had extended the no-shop period in its Letter of Intent with Global Tech Industries Group, Inc. (GTII) for its planned acquisition. Although there’s no guarantee a deal will be reached, both firms continue to evaluate the deal through due diligence, and Creatd is exploring a collar structure to potentially value its shares at $3.00 to $5.00 per share.

It would be interesting to see if GTII news gets picked up by retail investors causing a further surge in stock prices. We will update GTII when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s going on with GTII.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in GTII either long or short and we have not been compensated for this article

Continue Reading

BioPharma

Cosmos Holdings Inc (NASDAQ: COSM) Huge Short Position Panicks as COSM Rockets Up the Charts

Published

on

Cosmos Holdings Inc (NASDAQ: COSM) is rocketing up the charts northbound since reversing off $0.0675 lows earlier this month where we first gave the heads up on COSM at around a dime in our article here. Since than COSM has rocketed northbound recently surpassing $0.60 per share with speculators pointing at $1 as the next stop. In our previous article on COSM on November 13 when COSM was $0.10 we stated: “COSM was trading well over $3 at the beginning of this year but has been heavily shorted since than with current estimates of well over 5 million shares sold short and almost the entire public float sold short. 

While COSM has been heavily shorted into oblivion, the Company is actually doing quite well recently reporting revenues for the 3 months ended September 30 were $12 million. The Company is successfully developing their business recently closing a deal with Iberica, a European Airline, for in flight distribution of their products. The CEO has bought millions of shares at current levels and COSM is beginning to go viral on social media trending on the sub reddit Short Squeeze, Number #1 on Stocktwits and multiple videos being made on YouTube about a massive short squeeze taking place in small caps. 

COSM Friday December 2, 4PM Close Update: COSM had a wild trading day on Friday dropping to $0.42 in the morning before rocketing up to $0.61 highs. This was followed by another drop to the $0.47 range before COSM rocketed up in late afternoon trading, closing at $0.53 on 205 million shares traded. COSM was up 33% on the day on around $110 million in dollar volume. COSM is setup for an enormous week ahead, looking to overtake the $0.845 from Monday and embark on a blue-sky breakout with $1 as the first stop. We gave the heads up on COSM when the stock was below $0.10 per share at the beginning of November. We will be updating on COSM as soon as anything new happens so make sure you are subscribed to Microcapdaily by entering your email in the box below.  

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

No alternative text description for this imageCosmos Holdings Inc (NASDAQ: COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. 

The Number #2 post on the subreddit ShortSqueeze currently is titled: COSM about to test resistance. A pump through $0.66 and lift off to over $1.00 is possible now. 

In another post on COSM in the subreddit ShortSqueeze rubio2430 states: “$COSM you cant make this stuff up. this baby is ready for space. the shorts are burying themselves on the daily. constant pr’s, growing fundamentals, no plans on dilutions, dual listing on upstream soon—the list goes on! 

nimble_broccoli replied: Why this is a good play: 

1.) Extremely tiny Marketcap 2.) CEO buying 15’000’000 shares 3.) Good fundamentals, unlike other plays, they actually sell products valued around 10x the valuation. Q1/22 was profitable. 4.) Getting momentum on social media (Reddit Twitter, YT) 

Next catalysts: -Info that they will not be delisted from NASDAQ -Degen and Retail FOMO kicking in -Shorts starting to cover their asses 

In addition, consider this: The stock was somewhere between USD 2 and USD 12 the past ~8 years. Most Hodlers bought back then, do you think they will sell now? Do your own thinking but if one of my stocks dropped 80+ % i d not sell, i d just hope for a miracle or ride it out. Thus, not many regular buy&hold holders of the stock are expected to sell. 

Cosmos operates in the business of full-line pharmaceutical wholesale distribution and serves approximately 1,500 independent retail pharmacies and 40 pharmaceutical wholesalers in Greece region by providing brand-name and generic pharmaceuticals, over-the-counter medicines, vitamins and nutraceuticals. Cosmos invests in technology to enhance safety, distribution and warehousing efficiency and reliability. Specifically, the Company operates a fully automated warehouse system with three robotic systems, two ROWA™ types and one A-frame type, that ensure 0% error selection rate, accelerate order fulfillment, and yield higher cost-efficiency in our distribution center. Cosmos has 3 operating subsidiaries including:

SkyPharm
Sky Pharm SA is headquartered in Thessaloniki, Greece. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. We buy from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers, and export to European markets where demand and prices are substantially higher.
.
DHN
Decahedron Ltd. is a pharmaceutical wholesaler incorporated in the UK in August 2011. It is audited by the MHRA under European GDP (Good Distribution Practices). They are also a full member of the EAEPC and have been audited by TÜV on their behalf.
.
Cosmofarm
Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. The company is approved and authorized by the National Organization for Medicines under Good Distribution Practices to distribute a comprehensive range of pharmaceutical products. Cosmofarm’s core activity is sourcing, procuring, and distributing branded.
.
To Find out the inside Scoop on COSM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

COSM

Image

COSM business is strong and Q3 highlights include closing a $7.5M capital raise via public offering and signing an exclusive agreement to market and distribute Nickelodeon’s SpongeBob and PAW Patrol kids’ vitamins in Greece and Cyprus, aiming to reach out 11,000 pharmacies and 120 wholesalers in Greece and 780 pharmacies in Cyprus. They also executed a letter of intent for a strategic co-venture agreement with Smart for Life (SMLF) to cross market products and services in their reciprocal markets. COSM also entered into an LOI to acquire ZipDoctor Inc., and entered into an agreement with Virax Biolabs (VRAX), to become the distributor of Monkeypox Virus Real-Time PCR Detection Kits, having the exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the test kits across Europe on a non-exclusive basis. SkyPharm officially launched its first Sky Premium Life products on Amazon in the United States. Cosmos targets having all 85 SKUs listed on Amazon by year end. COSM entered into an LOI to acquire Pharmaceutical Laboratories CANA S.A., and another LOI to acquire LIFE NLB, Ltd.’s product portfolio, including Bone-Vio® and Bone-X, related to bone health targeting the human gastrointestinal microbiome. 

Last week COSM announced its Sky Premium Life luxury food supplement brand will be sold on Ronda, the official inflight magazine of the airline company Iberia of BRITISH AIRWAYS group. Ronda is available free of charge to the over 10 million passengers who fly Iberian Airlines annually. Iberia Airlines, majority owned by British Airways, has a fleet of 147 aircrafts and engages in over 600 daily flights. 

https://twitter.com/nxtplse/status/1597365583934545920

For More on COSM Subscribe Right Now!

Currently trading at a $36 million market valuation COSM os is 92,008,281 the Company recently reported Q3 Revenues of $12 million down a bit from the same time last year due to a high variation in FX differences between EUR and GBP to USD. COSM was trading over $4 this time last year however OS has increased substantially since then.  COSM is an exciting opportunity in small caps; the stock was shorted into oblivion and currently there are minimum 5.8 million shares short and was way oversold to pennies and it looked as if it would definitely get delisted by the Nasdaq however, led by able CEO Grigorios Siokas, Cosmos is fighting back. Mr. Siokas continues to buy more COSM at current price levels, putting his money where his mouth is as COSM rockets towards $1 which is now just a day and half away if the stock continues up at the same trend.  We will be updating on COSM when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in COSM either long or short and we have not been compensated for this article.

Continue Reading

BioPharma

Cosmos Holdings Inc (NASDAQ: COSM) Heating Up as Co Looks to Take on Massive 5 million Share Short Position

Published

on

Cosmos Holdings Inc (NASDAQ: COSM) is making a rapid move up the charts since recent reversing off $0.0675 lows. The stock was trading well over $3 at the beginning of this year but has been heavily shorted since than with current estimates of well over 5 million shares sold short and almost the entire public float sold short. COSM is quickly emerging as the latest short squeeze at the top of speculators watch lists and is currently trending on stocktwits and the sub reddit ShortSqueeze on Reddit. 

The Company is fighting back against the shorts and planning a lawsuit and CEO Grigorios Siokas recently put his money where his mouth is when he bought 12,500,000 shares of the stock at $0.12 average for about $1.5 million. While in danger of being delisted from the Nasdaq if they don’t get the stock price back over $1 by the end of November the Company is doing well recently reporting its first ever net income on $13,208,504 in revenues for the 3 months ended June 30, 2022. Cosmos is also acquiring ZipDoctor Inc. from American International Holdings Corp (AMIH) 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Cosmos Holdings Inc (NASDAQ: COSM) is an international healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. On August 2, 2022, the Company filed a Fictitious Firm Name Certificate in Nevada to do business under the name Cosmos Health, Inc. and will seek shareholder approval at its annual shareholders meeting scheduled for December 2, 2022 to amend its Articles of Incorporation for the name change. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and over-the-counter (“OTC”) medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors.  

Cosmos operates in the business of full-line pharmaceutical wholesale distribution and serves approximately 1,500 independent retail pharmacies and 40 pharmaceutical wholesalers in Greece region by providing brand-name and generic pharmaceuticals, over-the-counter medicines, vitamins and nutraceuticals. Cosmos invests in technology to enhance safety, distribution and warehousing efficiency and reliability. Specifically, the Company operates a fully automated warehouse system with three robotic systems, two ROWA™ types and one A-frame type, that ensure 0% error selection rate, accelerate order fulfillment, and yield higher cost-efficiency in our distribution center. Cosmos has 3 operating subsidiaries including:

SkyPharm
Sky Pharm SA is headquartered in Thessaloniki, Greece. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. We buy from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers, and export to European markets where demand and prices are substantially higher. The …
DHN
Decahedron Ltd. is a pharmaceutical wholesaler incorporated in the UK in August 2011. It is audited by the MHRA under European GDP (Good Distribution Practices). They are also a full member of the EAEPC and have been audited by TÜV on their behalf. They import and export branded, generic and …
Cosmofarm
Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. The company is approved and authorized by the National Organization for Medicines under Good Distribution Practices to distribute a comprehensive range of pharmaceutical products. Cosmofarm’s core activity is sourcing, procuring, and distributing branded

https://twitter.com/ChairmanOtc/status/1590877348752420866

To Find out the inside Scoop on COSM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

COSM

ImageOn August 22 Cosmos provided a business update and reported financial results for the second quarter and six months ended June 30, 2022. Revenues were $13,208,504 for the 3 months ended June 30, 2022 compared to $14.8 million for the same period last year. 

Greg Siokas, Chief Executive Officer of Cosmos Health, stated, “We increased our profitability for the first half of 2022 due to the increase of gross profit margin to 14.2% from 11.5% for the respective period of 2021. This increase is attributed mainly to the organic growth of our proprietary nutraceutical brand, Sky Premium Life® (“SPL”). We achieved positive income from operations of $0.2 million for the first half of 2022 compared to a loss of $3.1 million in the same period last year and positive EBITDA of $0.8 million for the first half of 2022 compared to a loss of $2.8 million for the same period last year. Gross profit increased by 23.0% to $3.7 million for the six months ended June 30, 2022. We continue to carefully manage expenses and reduced operating expenses by nearly 43.7% and 41.9% for the three and six months ended June 30, 2022, respectively. During the quarter, we launched a new premium line of nutritional supplements, Mediterranation. The Mediterranation line uses organic herbs and plant extracts such as crataegus, hibiscus, dittany of Crete, oregano, mastic and kritamos, found in specific regions in Greece and the Mediterranean. These unique formulations contain a proprietary blend of vitamins and minerals and are made with the highest quality raw materials. There is high demand among consumers for supplements that utilize high quality Mediterranean ingredients, such as polyphenols, which possess antioxidant and anti-inflammatory properties. We expect the launch of the Mediterranation line will further enhance our growth strategy and we look forward to expanding the product line into new global markets through our growing distribution channels. We also launched our SPL products on Amazon Singapore and are in the process of launching on Amazon United States and Amazon Canada in the third quarter of 2022. These new markets provide an untapped growth opportunities and new audiences for our proprietary SPL brand. Our goal is to grow our portfolio of branded nutraceuticals and reach up to 150 SKUs by the end of 2022.” 

Earlier this year Cosmos announced an LOI to acquire ZipDoctor Inc. from American International Holdings Corp (AMIH). AMIH will continue to manage all aspects of the day-to-day operations of ZipDoctor including product development, marketing, and operational support. ZipDoctor Inc., is a direct-to-consumer subscription-based telemedicine platform, that expects to provide its customers affordable, unlimited, 24/7 access to board certified physicians and licensed mental and behavioral health counselors and therapists. ZipDoctor’s online telemedicine platform will be available to customers across the United States and offers English and Spanish coverage with virtual visits taking place either via the phone or through a secured video chat platform. 

On October 17, 2022, Cosmos entered into a Securities Purchase Agreement with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a public offering, an aggregate of $7,500,000 of securities, consisting of (i) 62,500,000 shares of Common Stock, (ii) pre-funded Warrant in lieu of shares of Common Stock, and (iii) warrants to purchase 125,000,000 shares of Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”).  Under the terms of the Purchase Agreement, the Company agreed to sell one share of its Common Stock or a Pre-Funded Warrant and two Common Warrants for each share of Common Stock or Pre-Funded Warrant sold at a unit price of $0.12.  For each of 15,662,603 Pre-Funded Warrant sold in the Offering, the number of shares of Common Stock offered were decreased on a one-for-one basis. 

https://twitter.com/AirGoodman24/status/1591938222548189186

 For More on COSM Subscribe Right Now!

Currently trading at a $10 million market valuation COSM is the latest potential short squeeze at the top of speculators watch lists. With $35 million in current liabilities and an inability to collect on accounts receivables that currently stand at over $25 million COSM stock has lagged even as the Company reports its first ever net income on $13,208,504 in revenues for the 3 months ended June 30, 2022. The short position on COSM has grown to well over 5 million shares short and currently the entire public float is sold short. Now that the cat is out of the bag and the stock is surging northbound COSM short squeeze should be at the top of small cap speculators watch lists. We will be updating on COSM when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in COSM either long or short and we have not been compensated for this article.

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.